Abstract
Recent evidence has suggested improved outcomes following incorporation of intraperitoneal chemotherapy administration with intravenous systemic chemotherapy as first-line treatment of small volume residual epithelial ovarian cancer. This review focuses on the mechanism of actions of the chemotherapeutic drugs and reviews the possible reasons for the superior outcomes of intraperitoneal chemotherapy.
Keywords: Intraperitoneal chemotherapy, cisplatin, carboplatin, paclitaxel, ovarian cancer management
Mini-Reviews in Medicinal Chemistry
Title: Intraperitoneal Chemotherapy as First-Line Treatment in the Management of Epithelial Ovarian Cancer
Volume: 7 Issue: 5
Author(s): S. Rekhraj, J. Kinross, S. Prabhudesai, A. Darzi and P. Ziprin
Affiliation:
Keywords: Intraperitoneal chemotherapy, cisplatin, carboplatin, paclitaxel, ovarian cancer management
Abstract: Recent evidence has suggested improved outcomes following incorporation of intraperitoneal chemotherapy administration with intravenous systemic chemotherapy as first-line treatment of small volume residual epithelial ovarian cancer. This review focuses on the mechanism of actions of the chemotherapeutic drugs and reviews the possible reasons for the superior outcomes of intraperitoneal chemotherapy.
Export Options
About this article
Cite this article as:
Rekhraj S., Kinross J., Prabhudesai S., Darzi A. and Ziprin P., Intraperitoneal Chemotherapy as First-Line Treatment in the Management of Epithelial Ovarian Cancer, Mini-Reviews in Medicinal Chemistry 2007; 7 (5) . https://dx.doi.org/10.2174/138955707780619644
DOI https://dx.doi.org/10.2174/138955707780619644 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biologically Active Selenophenes and Benzo[b]selenophenes
Current Organic Synthesis Targeting Translation for Treatment of Cancer - A Novel Role for IRES?
Current Cancer Drug Targets Review on Documented Medicinal Plants used for the Treatment of Cancer
Current Traditional Medicine Enhanced Expression of miR-199b-5p Promotes Proliferation of Pancreatic β-Cells by Down-Regulation of MLK3
MicroRNA Isoflavones, Equol and Cardiovascular Disease: Pharmacological and Therapeutic Insights
Current Medicinal Chemistry MicroRNAs: Potential Diagnostic and Therapeutic Targets for Breast Cancer
Epigenetic Diagnosis & Therapy (Discontinued) DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis
Current Pharmaceutical Design Ganoderma lucidum: A Potential for Biotechnological Production of Anti-Cancer and Immunomodulatory Drugs
Recent Patents on Anti-Cancer Drug Discovery Sphingolipid Metabolism and Drug Resistance in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Effect-based Hazard Identification of House Dust by In Vitro Assays Detecting Dioxin-like Compounds, Thyroid and Reproductive Toxicants
Current Organic Chemistry Apoptotic Effects of N-(2-Hydroxyphenyl)-2-Propylpentanamide on U87-MG and U-2 OS Cells and Antiangiogenic Properties
Anti-Cancer Agents in Medicinal Chemistry Mining Sarcomas by Proteomics Approaches: Ewing Sarcoma on the Spotlight
Recent Patents on Biotechnology Oral Precancerous Lesions Show Increased Levels of Glutathione Compared to Cancerous Tissue
Current Nutrition & Food Science Galanthus nivalis Agglutinin (GNA)-Related Lectins: Traditional Proteins, Burgeoning Drugs?
Current Chemical Biology Emerging Role of Mucins in Epithelial to Mesenchymal Transition
Current Cancer Drug Targets Determinants of Anti-Cancer Effect of Mitochondrial Electron Transport Chain Inhibitors: Bioenergetic Profile and Metabolic Flexibility of Cancer Cells
Current Pharmaceutical Design 5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs)
Current Medicinal Chemistry Nanoparticles for Cancer Targeting: Current and Future Directions
Current Drug Delivery